ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines

Blood

Volumn 113, Issue 16, 2009, Pages 3813-3820

  Nardi, Valentina ^a   Naveiras, Olaia ^a   Azam, Mohammad ^a   Daley, George Q ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BCR ABL PROTEIN; BETA INTERFERON; CCL6 CHEMOKINE; CCL9 CHEMOKINE; CHEMOKINE; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; UNCLASSIFIED DRUG; BETA CHEMOKINE; CCL6 PROTEIN, MOUSE; CCL9 PROTEIN, MOUSE; INTERFERON; INTERFERON REGULATORY FACTOR; MACROPHAGE INFLAMMATORY PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CANCER PREVENTION; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE INDUCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR IMMUNITY; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL STRAIN K 562; DISEASE MODEL; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; ONCOGENE;

ANIMALS; CHEMOKINES, CC; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, ABL; HUMANS; INTERFERON REGULATORY FACTORS; INTERFERON TYPE I; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MACROPHAGE INFLAMMATORY PROTEINS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT;

EID: 65549126031     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-167189     Document Type: Article

References (48)

1. Hoover RR, Gerlach MJ, Koh EY, Daley GQ. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene. 2001;20:5826-5835.
2. Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood. 1995;86:726-736.
3. Sattler M, Griffin JD. Mechanisms of transformation by the BCR/ABL oncogene. Int J Hematol. 2001;73:278-291.
4. Ren R. The molecular mechanism of chronic my-elogenous leukemia and its therapeutic implications: studies in a murine model. Oncogene. 2002;21:8629-8642.
5. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev. 1998;12:968-981. (Pubitemid 28204604)
6. Kantarjian HM, O'Brien S, Cortes JE, et al. Complete cytogenetic and molecular responses to interferon- alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003;97:1033-1041. (Pubitemid 36173155)
7. Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001; 98:3074-3081.
8. Mahon FX, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol. 2002;20: 214-220. (Pubitemid 34032614)
9. Lee MS, Kantarjian H, Talpaz M, et al. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood. 1992;79:1920-1923.
10. Hochhaus A, Lin F, Reiter A, et al. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha. Br J Haematol. 1995; 91:126-131.
11. Kujawski LA, Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev. 2007;18:459-471. (Pubitemid 47302836)
12. Burchert A, Wolfl S, Schmidt M, et al. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood. 2003;101:259-264. (Pubitemid 36025916)
13. Molldrem JJ, Clave E, Jiang YZ, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 1997; 90:2529-2534.
14. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6:1018-1023.
15. Holtschke T, Lohler J, Kanno Y, et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell. 1996;87:307-317. (Pubitemid 26359008)
16. Hao SX, Ren R. Expression of interferon consensus sequence binding protein (ICSBP) is down-regulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol Cell Biol. 2000; 20:1149-1161. (Pubitemid 30069235)
17. Deng M, Daley GQ. Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia. Blood. 2001;97:3491-3497.
18. Burchert A, Cai D, Hofbauer LC, et al. Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood. 2004;103:3480-3489. (Pubitemid 38525681)
19. Tamura T, Kong HJ, Tunyaplin C, Tsujimura H, Calame K, Ozato K. ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells. Blood. 2003;102:4547-4554. (Pubitemid 37494123)
20. Schmidt M, Bies J, Tamura T, Ozato K, Wolff L. The interferon regulatory factor ICSBP/IRF-8 in combination with PU. 1 up-regulates expression of tumor suppressor p15(Ink4b) in murine myeloid cells. Blood. 2004;103:4142-4149.
21. Schmidt M, Nagel S, Proba J, et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood. 1998;91:22-29. (Pubitemid 28018725)
22. Tamura T, Nagamura-Inoue T, Shmeltzer Z, Kuwata T, Ozato K. ICSBP directs bipotential myeloid progenitor cells to differentiate into mature macrophages. Immunity. 2000;13:155-165. (Pubitemid 30951882)
23. Tsujimura H, Nagamura-Inoue T, Tamura T, Ozato K. IFN consensus sequence binding protein/IFN regulatory factor-8 guides bone marrow progenitor cells toward the macrophage lineage. J Immunol. 2002;169:1261-1269. (Pubitemid 34809167)
24. Schiavoni G, Mattei F, Sestili P, et al. ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells. J Exp Med. 2002;196:1415-1425. (Pubitemid 35424936)
25. + dendritic cells. Blood. 2003; 101:305-310.
26. Palacios R, Steinmetz M. Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell. 1985;41:727-734. (Pubitemid 15225429)
27. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 2003;112:831-843. (Pubitemid 36378885)
28. Azam M, Raz T, Nardi V, Opitz SL, Daley GQ. A screen to identify drug resistant variants to target-directed anti-cancer agents. Biol Proced Online. 2003;5:204-210. (Pubitemid 38097516)
29. Driggers PH, Ennist DL, Gleason SL, et al. An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc Natl Acad Sci U S A. 1990;87:3743-3747. (Pubitemid 20182535)
30. Ilaria RL Jr, Van Etten RA. The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells. Blood. 1995;86:3897-3904.
31. Peters DG, Hoover RR, Gerlach MJ, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001;97:1404-1412.
32. Fernandez de Mattos S, Essafi A, Soeiro I, et al. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol Cell Biol. 2004;24:10058-10071.
33. Cilloni D, Messa F, Arruga F, et al. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia. 2006;20:61-67.
34. Hara T, Bacon KB, Cho LC, et al. Molecular cloning and functional characterization of a novel member of the C-C chemokine family. J Immunol. 1995;155:5352-5358.
35. Moffat J, Grueneberg DA, Yang X, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 2006;124:1283-1298.
36. Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet. 2003;33:401-406. (Pubitemid 36278858)
37. Porter DL, Antin JH. The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med. 1999;50:369-386.
38. Leis J, Porter DL. Unrelated donor leukocyte infusions to treat relapse after unrelated donor bone marrow transplantation. Leuk Lymphoma. 2002; 43:9-17. (Pubitemid 34223966)
39. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462-2465.
40. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041-2050.
41. Jiang YZ, Barrett AJ, Goldman JM, Mavroudis DA. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol. 1997;74:1-6.
42. Krause DS, Van Etten RA. Adoptive immuno-therapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model. Blood. 2004;104:4236-4244.
43. + dendritic cells. J Immunol. 2003;171:2797-2803.
44. Coelho AL, Schaller MA, Benjamim CF, Orlofsky AZ, Hogaboam CM, Kunkel SL. The chemokine CCL6 promotes innate immunity via immune cell activation and recruitment. J Immunol. 2007;179: 5474-5482.
45. Iotti G, Ferrari-Amorotti G, Rosafio C, et al. Expression of CCL9/MIP-1gamma is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells. Oncogene. 2007;26:3482-3491.
46. Pawelec G, Da Silva P, Max H, et al. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha. Leuk Lymphoma. 1995;18:471-478.
47. de Castro FA, Palma PV, Morais FR, et al. Immunological effects of interferon-alpha on chronic myelogenous leukemia. Leuk Lymphoma. 2003; 44:2061-2067.
48. Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of hematologic malignancy. Hematology Am Soc Hematol Educ Program. 2003:331-349.